Macrophages as novel targets for ameliorating deleterious complement activation in retinal degeneration

Age-related macular degeneration (AMD) is the most common cause of blindness in Australia, although there few effective treatments. Without fresh understanding into its underlying cause, its incidence is expected to double by 2030. This research will lend new insight into how innate immune pathways drive noxious inflammation in AMD, which will help guide the development of novel antiinflammatory therapeutics to help ease its socio-economic burden on Australians.